This week (9/22) we launched an IRB (Institutional Review Board) study in partnership with UCSD. With the help and support of UCSD radiologists, CureMetrix will take a deep dive into early detection of breast cancer.
The IRB will focus first on mammograms, later continuing to explore other modalities such as ultrasound, CT scans, and MRI. With the help of our Principal Investigator, CureMetrix will work with anonymized images that will be used to train CureMetrix’ proprietary learning algorithm to detect and correctly classify cancers.
Once the efficacy of the algorithm on this blind, controlled study has been demonstrated, the IRB will continue with the testing and validation of novel data to prove the accuracy of the CureMetrix anomaly detection algorithm.